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A cellular energetics primer
The First Law of Thermodynamics states that the total amount
of energy in a system remains constant before and after any
sort of transforming event. The Second Law of Thermo-
dynamics states that, even though the total amount of energy
does not change after a transforming event, the total amount
of usable energy (the Gibbs free energy) is always
decreased. In accordance with the Second Law of Thermo-
dynamics, all reversible chemical reactions proceed in the
direction that results in a net decrease in the Gibbs free
energy for the system; in other words, the change in the
Gibbs free energy (∆G) is always less than zero.
When cells in living systems need to carry out a reaction for
which ∆G is positive, they couple the reaction to another reac-
tion that is energetically favorable (i.e. characterized by
∆G < 0). If the algebraic sum of the ∆G values for the two
coupled reactions is negative then the formation of the desired
product can proceed. For example, the amidation of glutamate
by an ammonium ion to form glutamine is an ‘endergonic’
reaction (∆G > 0). To drive this reaction toward the formation
of glutamate, cells couple it to another reaction, the hydrolysis
of ATP to form ADP and inorganic phosphate, which is ‘exer-
gonic’ (∆G is negative). The algebraic sum of ∆G for the two
reactions is negative, and the coupled reactions proceed
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Abstract
The rate of oxygen consumption by certain tissues is impaired when mice or rats are injected with
lipopolysaccharide. A similar change in the rate of oxygen consumption is observed when Caco-2
human enterocyte-like cells are incubated in vitro with cytomix, a cocktail of cytokines containing tumor
necrosis factor, IL-1β, and IFN-γ. The decrease in the rate of oxygen consumption is not due to a
change in oxygen delivery (e.g. on the basis of diminished microvascular perfusion), but rather to an
acquired intrinsic defect in cellular respiration, a phenomenon that we have termed ‘cytopathic
hypoxia’. A number of different biochemical mechanisms have been postulated to account for
cytopathic hypoxia in sepsis, including reversible inhibition of cytochrome a,a3 by nitric oxide, and
irreversible inhibition of one or more mitochondrial respiratory complexes by peroxynitrite. Recently,
however, our laboratory has obtained data to suggest that the most important mechanism underlying
the development of cytopathic hypoxia is depletion of cellular stores of nicotinamide adenine
dinucleotide (NAD+/NADH) as a result of activation of the enzyme, poly(ADP-ribose) polymerase-1. If
cytopathic hypoxia is important in the pathophysiology of established sepsis and multiorgan
dysfunction syndrome, then efforts in the future will need to focus on pharmacological interventions
designed to preserve normal mitochondrial function and energy production in sepsis.
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yielding the products glutamine, ADP, inorganic phosphate,
and a hydrogen ion.
Hundreds of reactions within cells would not proceed without
this sort of coupling. Also, in most cases, the exergonic reac-
tion that drives the formation of the desired product is
hydrolysis of the terminal pyrophosphate ester linkage of ATP
to yield ADP and inorganic phosphate. The hydrolysis of ATP
also drives other energy-requiring processes in cells, such as
the active pumping of solutes against a concentration gradi-
ent across a membrane barrier. Therefore, for proper func-
tioning, all cells need a steady supply of ATP. Stated another
way, ATP is the energy currency of the cell.
ATP can be generated in cells as a result of both aerobic and
anaerobic processes. Anaerobic generation of ATP, or the
energetically equivalent compound guanosine triphosphate,
occurs in both the cytosol and mitochondria as a result of the
phosphorylation reactions that are catalyzed by the enzymes
phosphoglycerate kinase, pyruvate kinase, and succinyl co-
enzyme A synthase (Fig. 1). Aerobic generation of ATP
occurs in the mitochondria as a result of a carefully orches-
trated series of reactions that effectively couple the oxidation
of substrates by molecular oxygen (O2), on the one hand, to
the phosphorylation of ADP to form ATP, on the other.
To provide a somewhat more detailed account of oxidative
phosphorylation, it is will be useful to briefly review the basic
principles of reduction–oxidation (redox) chemistry. Good
reducing agents are elements or compounds that have a
strong propensity to donate electrons to another element or
compound. Conversely, good oxidizing agents are elements
or compounds that avidly accept electrons. Molecular oxygen
(dioxygen, O2) is a very potent oxidizing agent. Two strong
reducing agents, namely the reduced form of nicotinamide
adenine dinucleotide (NADH) and the reduced form of flavin
adenine dinucleotide, are produced in cells during glycolysis
and the citric acid cycle. These two reducing agents are oxi-
dized by O2 in mitochondria, and the energy released during
this process is used to drive the formation of ATP.
The reaction of a strong reducing agent such as NADH with a
powerful oxidizing agent such as O2 releases a large amount
of energy. To take optimal advantage of this highly exergonic
redox reaction and to capture as much of the energy released
as possible in a usable form (i.e. the high-energy terminal
pyrophosphate bond in ATP), mitochondria ‘step-down’ the
reducing potential of NADH (and the reduced form of flavin
adenine dinucleotide) in stages. The electrons are thus not
transferred from NADH to O2 all at once, but rather are trans-
ferred through a series of intermediate compounds, called
electron carriers, that have progressively lower reducing
potentials. Several of the electron carriers involved in the
mitochondrial respiratory chain are organized as complexes
located within the inner mitochondrial membrane. These com-
plexes use the energy released during electron transfer to
actively pump protons from the mitochondrial matrix into the
intermembrane space, thereby generating an electrochemical
gradient across the inner mitochondrial membrane. The pres-
ence of this gradient drives hydrogen ions through a mito-
chondrial enzyme, the FoF1ATPase, that catalyzes the
formation of ATP from ADP and inorganic phosphate.
For each mole of glucose metabolized to carbon dioxide and
water, the net yield of ATP from substrate level (anaerobic)
phosphorylation reactions is 4 moles of ATP, whereas the net
yield of ATP from oxidative phosphorylation reactions is
32 moles of ATP. The oxidative metabolism in normally func-
tioning mitochondria is thus far more efficient at producing
ATP than is the anaerobic metabolism, and many cell types
(such as hepatocytes, neurons, and cardiac myocytes) are
dependent on a steady supply of O2.
Evidence for impaired mitochondrial
respiration in sepsis
Many factors can compromise the delivery of O2 to tissues in
patients with sepsis. Among these factors are acute lung
injury, which of course can cause arterial hypoxemia. In addi-
tion, dilation of capacitance vessels combined with microvas-
cular hyperpermeability can lead to an acute decrease in the
left ventricular preload and can thereby compromise cardiac
output. Left ventricular performance can be further compro-
mised by the intrinsic decrease in myocardial contractility that
occurs in many patients with sepsis. Perfusion through the
microvasculature can also be embarrassed by abnormalities
in arteriolar tone as well as plugging of capillaries by
sequestered platelets and leukocytes. In addition, the
deformability of erythrocytes is impaired in patients with
sepsis, and this pathological phenomenon might further con-
tribute to derangements in microvascular blood flow.
Given the importance of impaired perfusion in sepsis, it is not
surprising that intensivists have focused enormous effort on
Figure 1
Biochemical reactions that result in substrate level phosphorylation of
either ADP or guanosine diphosphate (GDP). The products of these
reactions are ATP and guanosine triphosphate (GTP), respectively.
CoA, coenzyme A.
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developing better ways to monitor blood flow and O2 delivery.
Furthermore, convincing data are now available to support the
view that early aggressive efforts to improve systemic O2 deliv-
ery by administering intravenous fluids, packed red blood cells,
and inotropic agents can improve the outcome for patients with
septic shock [1]. By the same token, however, efforts to
improve systemic O2 delivery later in the course of sepsis are at
best ineffective [2,3], and at worst deleterious [4].
If improving perfusion and O2 delivery in patients with estab-
lished sepsis fails to improve survival or prevent organ system
dysfunction, then one might wonder whether alterations in
energy metabolism are important at all in the pathogenesis of
the syndrome [5]. Alternatively, one could hypothesize that
cellular energetics are deranged in sepsis not just because
O2 delivery is impaired, but also, and perhaps even more
importantly, because the ability of cells to utilize available O2
is compromised.
Some years ago, we coined the term ‘cytopathic hypoxia’ to
describe just such an acquired intrinsic derangement in cellu-
lar respiration [6,7]. While the clinical significance of this phe-
nomenon remains to be established with certainty, a
considerable body of evidence has accumulated to support
the notion that cytopathic hypoxia occurs in experimental
animals with sepsis or endotoxemia or cells exposed in vitro
to proinflammatory cytokines. Moreover, it is becoming
increasingly apparent that activation of a key enzyme,
poly(ADP-ribose) polymerase-1 (PARP-1), plays a central role
in the pathogenesis of cytopathic hypoxia. The purpose of the
present article is to review some of these data.
Measurements of tissue oxygen partial pressure and
the cytochrome a,a3 redox state
Tissue hypoxia is an expected correlate of any of the three
classical causes of impaired cellular aerobic metabolism iden-
tified by Barcroft more than 75 years ago [8]. Therefore,
when the delivery of O2 decreases on the basis of low arterial
oxygen tension (pO2), anemia, and/or hypoperfusion, cells
extract a greater fraction of the available O2 in an effort to
defend aerobic ATP production. As a consequence, the dis-
tribution of tissue pO2 values shifts to the left (i.e. toward
values closer to zero). In contrast, when ATP production is
impaired as a result of an intrinsic derangement in cellular
respiration, cells extract less O2 per unit time from the avail-
able supply. The expected consequence of this change in O2
extraction is a rightward shift of the tissue pO2 distribution
(i.e. toward higher values).
One line of evidence supporting the concept of cytopathic
hypoxia comes from studies making measurements of tissue
pO2 in patients or experimental animals. If tissue hypoperfu-
sion were a major factor contributing to cellular dysfunction in
sepsis, septic shock, or endotoxemia, then we would predict
that abnormally low values for tissue pO2 would be detected
in these conditions. But, if impaired O2 utilization by cells
were a major factor, then we would predict that tissue pO2
values would be normal or even higher than normal. Indeed,
observations of this sort have been reported. For example,
Astiz and colleagues used cecal ligation and puncture in rats
as a model of sepsis. They showed that the mean skeletal
muscle pO2 was similar in septic animals and in normal con-
trols provided that the rats with peritonitis were infused with
albumin solution to expand the intravascular volume [9].
In a conceptually similar study, Hotchkiss et al. used a novel
approach to determine whether tissue hypoxia occurs follow-
ing the induction of sepsis in rats [10]. The tissue pO2 was
not measured directly, but rather was estimated by measuring
the retention of [18F]fluoroisonidazole, a lipophilic 2-nitro-
imidazole derivative that is irreversibly bound to intracellular
macromolecules under hypoxic, but not normoxic, conditions.
As a positive control, these investigators showed that reten-
tion of [18F]fluoroisonidazole was increased in gastrocnemius
muscle rendered ischemic by proximal application of a rubber
tourniquet. When the retention of [18F]fluoroisonidazole in a
variety of tissues, such as skeletal muscle and the liver, was
compared in groups of septic rats and of nonseptic controls,
however, no differences were apparent. These data provided
very strong evidence that sepsis in rats is not associated with
tissue hypoxia.
Some data support the even more remarkable conclusion that
the tissue pO2 actually increases in sepsis relative to normal
values. For example, VanderMeer et al. used a porcine model
to investigate the effects of endotoxemia on intestinal
mucosal pO2 [11]. When anesthetized pigs were infused with
lipopolysaccharide (LPS) and simultaneously resuscitated to
maintain normal cardiac output, the mean mucosal pO2
increased significantly (Fig. 2). Rosser et al. similarly reported
that bladder mucosal pO2 increased in rats challenged with
LPS [12]. The very same pattern has been observed in
humans. Boekstegers and colleagues documented that the
pO2 distribution in skeletal muscle was shifted toward values
less than normal in patients with cardiogenic shock, as
expected, but was shifted to the right (i.e. to supranormal
values) in patients with septic shock [13]. Sair et al. also
recently reported that skeletal muscle tissue pO2 levels are
higher than normal in patients with severe sepsis [14]. These
data showing that the tissue pO2 actually increases during
sepsis are consistent with the view that cellular utilization of
O2 is impaired under these conditions.
This same idea is also supported by another related study.
Simonsen et al. used near-infrared spectroscopy to monitor
the redox state of the terminal element of the mitochondrial
respiratory chain, cytochrome a,a3, in skeletal muscle cells of
baboons rendered septic by an infusion of viable Escherichia
coli [15]. The functional status of cytochrome a,a3 was moni-
tored by periodically causing temporary skeletal muscle
ischemia using a proximally placed tourniquet. Inflating the
tourniquet caused a decrease in the signal from oxidized
Available online http://ccforum.com/content/6/6/491494
cytochrome a,a3, whereas deflating the tourniquet resulted in
an increase in the near-infrared signal from the reoxidized
enzyme. Early in the sepsis protocol (i.e. at 6 hours), the rate
of cytochrome a,a3 reduction following tourniquet ischemia
was the same as that at baseline, although the rate of reoxida-
tion following the release of ischemia was slowed. These data
were interpreted as being consistent with decreased delivery
of O2 to the tissue. Later in the sepsis protocol (e.g. at
18 hours), the rate of cytochrome a,a3 reduction during
tourniquet ischemia was markedly slowed, a finding that was
felt to be consistent with the presence of either a defect in
the ability of the enzyme to accept electrons from O2 or a lim-
itation in the availability of reducing equivalents (i.e. NADH
and/or the reduced form of flavin adenine dinucleotide).
These data are particularly interesting because they suggest
that cytopathic hypoxia is not present early in sepsis, but that
it develops after the septic process has evolved for many
hours. These temporal considerations might explain the posi-
tive results obtained in a clinical trial of ‘early goal-directed’
hemodynamic support by Rivers et al. [1] and the negative
results obtained in a similar trial but including patients with
more established disease [4].
It is important to point out that not all studies of sepsis have
obtained data showing that tissue pO2 values are normal or
increased. Indeed, contrary findings have been reported by a
number of investigators. For example, two well-performed
studies showed that the intestinal mucosal pO2 decreased
when experimental animals were infused with LPS to a
sepsis-like state [16,17]. Sair and colleagues similarly
reported that the skeletal muscle pO2 decreased markedly in
a rat model of endotoxemia [18]. Interestingly, in the study by
Sair  et al. there was no difference between endotoxemic
animals and controls with respect to skeletal muscle perfu-
sion. The development of tissue hypoxia following the injec-
tion of LPS was therefore attributed to impaired
microvascular control of nutritive flow.
Indirect and direct measurements of mitochondrial
respiration
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) is a colorless compound that is reduced by functioning
mitochondria to a blue dye (MTT-formazan). The concentra-
tion of the blue product can be determined spectrophotomet-
rically. The reduction of MTT is thus a convenient, albeit
indirect, way to assess mitochondrial function.
Bankey et al. used this approach in 1974 to assess mitochon-
drial function in cocultures of rat hepatoctyes and rat liver
macrophages [19]. Sequential stimulation of the cultures with
a proinflammatory cytokine (IL-6) and then LPS decreased
MTT reduction by about 50%. Similar results were reported
more recently by Szabó and colleagues, who showed that
MTT reduction was decreased in cultured macrophages and
vascular smooth muscle cells following incubation with a
proinflammatory cytokine (IFN-γ) plus LPS [20].
Unno et al. used the reduction of MTT to MTT-formazan to
assess mitochondrial function in vivo [21]. In that study, rats
were injected with saline or a low dose of LPS (5 mg/kg) that
caused neither hypotension nor mortality. Twenty-four hours
later, the lumen of the intestine was loaded with a solution of
MTT. After a 30 min incubation period, the epithelial layer was
scraped off the intestine and the concentration of MTT-
formazan in enterocytes was determined spectrophoto-
metrically. The MTT reduction was shown to be significantly
lower in enterocytes from endotoxemic rats as compared with
enterocytes from normal controls (Fig. 3). In the study by
Unno  et al., treatment of the endotoxemic rats with
aminoguanidine, a drug that blocks inducible nitric oxide syn-
thase (iNOS), restored MTT reduction back to normal levels.
This latter finding suggests that impaired mitochondrial respi-
ration in sepsis is mediated, at least partially, by a mechanism
that depends on increased production of nitric oxide free
radical (NO·) via the iNOS pathway.
The MTT assay reflects the activity of a number of different
dehydrogenases, particularly succinate dehydrogenase [22],
and is not a direct measure of mitochondrial O2 consumption
per se. Several studies have obtained more direct evidence
that cellular or mitochondrial respiration is impaired in animals
with sepsis or endotoxemia. For example, Kantrow et al.
showed that hepatocytes isolated from septic rats consumed
significantly less O2  than did hepatocytes from nonseptic
control rats [23]. King et al. subsequently sought to deter-
mine whether ileal mucosal O2 consumption is impaired in
endotoxemic rats [24]. Rats were injected with either LPS or
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Figure 2
Ileal mucosal oxygen tension in pigs infused with lipopolysaccharide
(LPS) (150 µg/kg; n = 6) or normal saline (n = 4). The animals were
resuscitated with lactated Ringer’s solution and dextran-70 solution to
maintain a cardiac output of 90–110% of the baseline value. Mucosal
oxygen tension (pO2) histograms were obtained with an array of Clark-
type O2-sensitive electrodes driving an amplifier and a computerized
data acquisition system. Adapted from [11] with permission.
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a similar volume of the saline vehicle. Eight hours later, a strip
of ileal mucosa was harvested from the animals and mounted
in a polaragraphic chamber, and the rate of O2 consumption
determined using standard methods. The rate of O2 con-
sumption was significantly lower for mucosal samples from
endotoxemic rats as compared with control rats (Fig. 4). If the
endotoxemic rats were treated with aminoguanidine to block
iNOS activity, then normal ileal mucosal O2 consumption was
preserved. These findings thus provide further support for the
notion that the development of cytopathic hypoxia in LPS-
challenged rats requires iNOS-dependent NO· production.
Potential mechanisms to explain cytopathic
hypoxia in sepsis
A number of different but mutually compatible mechanisms
might foster the development of cytopathic hypoxia under
pathological conditions. These mechanisms include the
diminished delivery of pyruvate into the mitochondrial tricar-
boxylic acid (TCA) cycle, the inhibition of key mitochondrial
enzymes that are involved in either the TCA cycle or the
electron transport chain, and the activation of the enzyme
PARP-1.
Inhibition of pyruvate dehydrogenase
The end-product of glycolysis is pyruvic acid, a three-carbon
alpha-keto acid. Pyruvic acid can either be reduced to lactic
acid or enter the TCA, ultimately to be oxidized to water and
carbon dioxide. Pyruvate dehydrogenase (PDH) catalyzes the
reaction whereby pyruvate, in the presence of NAD+ and
coenzyme A, is converted to acetyl-coenzyme A. Because of
its pivotal role in the regulation of intermediary metabolism,
the activity of PDH is tightly regulated by both end-product
inhibition and reversible phosphorylation. A group of isoen-
zymes, the PDH kinase family, catalyzes the phosphorylation
of PDH to its inactive form. A PDH phosphatase catalyzes the
dephosphorylation of the inactive form to the active form of
the enzyme complex. Vary and coworkers showed that the
PHH inactive form:PHA active form ratio in skeletal muscle
tissue increases during chronic sepsis in rats [25,26]. The
mechanism responsible for this effect is increased PDH
kinase activity rather than decreased PDH phosphatase activ-
ity [27,28]. Because inactivation of PDH limits the flux of the
substrate through the TCA cycle, excess pyruvate accumu-
lates in cells and leads to increased production of lactate.
Therefore, according to the data obtained by Vary’s labora-
tory, hyperlactatemia in sepsis is not necessarily evidence of
impaired O2 delivery, but can be evidence of the combined
effects of PDH inhibition and accelerated glucose transport
into cells [26].
Nitric oxide-mediated inhibition of cytochrome a,a3
As already noted, sepsis is associated with iNOS induction
and increased production of the pluripotent signaling and
effector molecule NO·. At physiologically relevant concentra-
tions (~1 µM), NO· rapidly but reversibly inhibits the enzymatic
activity of cytochrome a,a3, the terminal complex of the mito-
chondrial electron transport chain [29–32]. NO·-mediated
inhibition of mitochondrial O2 consumption is the result of
competition by the two gases (i.e. O2 and NO·) for the same
binding site on the enzyme complex [33,34]. Accordingly, the
inhibitory effect of NO· tends to be more pronounced when
the pO2 is relatively low [30–32]. Although much of the work
related to this mechanism has been carried out using NO·
derived from an exogenous source (i.e. authentic NO· gas or
a chemical compound that releases NO· in solution), data are
Available online http://ccforum.com/content/6/6/491
Figure 3
Effect of lipopolysaccharide (LPS) on the ileal mucosal mitochondrial
function in rats. Rats were injected with normal saline (NS), LPS
(5 mg/kg) or the same dose of LPS plus aminoguanidine (AG). The
mitochondrial function was measured 24 hours later using MTT (see
text). * P < 0.05 versus NS, † P < 0.05 versus LPS. Adapted from [21]
with permission.
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Figure 4
Effect of lipopolysaccharide (LPS) on ileal mucosal O2 consumption.
Rats in the NS/NS group were injected at T = 0 hours with normal
saline (NS) and were treated with NS. Rats in the LPS/NS group were
injected with LPS (5 mg/kg) at T = 0 hours and were treated with NS.
Rats in the LPS/AG group were challenged with the same dose of
LPS and treated with aminoguanidine (30 mg/kg per dose at T = 1, 3
and 6 hours). Ex vivo O2 consumption was measured at T = 8 hours.
Adapted from [24] with permission.
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available to show that endogenously produced NO· is also
capable of causing reversible inhibition of the terminal
element in the mitochondrial respiratory chain (cytochrome
a,a3), leading to reduced cellular respiration [35].
Peroxynitrite-mediated inhibition of mitochondrial
enzymes
Although NO· reversibly inhibits cytochrome a,a3, the com-
pound reacts with only a limited range of intracellular targets
and should not be regarded as toxic. Under the right condi-
tions, however, NO· reacts rapidly with O2
–· to form peroxy-
nitrite (ONOO–), which is a potent oxidizing and nitrosating
agent [36–39]. Appropriate conditions for the production of
ONOO– are present during a variety of acute inflammatory
conditions, including ischemia/reperfusion injury and sepsis.
In addition, small quantities of O2
–· are continually being pro-
duced by mitochondria at the level of the three enzymatic
complexes interacting with Q10. Under certain conditions,
such as when O2 availability is limited [40] or cytochrome a,a3
is inhibited by NO· [41], mitochondria generate increased
quantities of O2
–· by this mechanism. Moreover, a calcium-
dependent nitric oxide synthase isoform that is either identical
to or is very similar to neuronal nitric oxide synthase is present
in mitochondria [42–45]. Mitochondria are thus capable,
within the confines of the organelle itself, of generating both
NO· and O2
–·, and hence, under appropriate conditions, large
quantities of the potentially toxic moiety ONOO– [46].
In the laboratory, exposing mitochondria to ONOO– from an
exogenous source causes irreversible inhibition of mitochon-
drial respiration. Several mechanisms have been implicated
as being important in this phenomenon. Specifically, ONOO–
has been shown to inhibit the mitochondrial FoF1ATPase that
carries out phosphorylation of ADP to form ATP [47]. In addi-
tion, ONOO– also inhibits two of the mitochondrial enzyme
complexes, namely Complex I [47] and Complex II [47], that
are involved in electron transport. {Note added in proof:
Brealey  et al. recently reported that Complex I activity in
skeletal muscle biopsies from patients with sepsis is inversely
correlated with plasma nitrite/nitrate levels (marker for NO·
production) and shock severity [48].} Finally, ONOO– inhibits
the activity of aconitase, the TCA cycle enzyme that converts
citrate into isocitrate [49]. Endogenous production of
ONOO– secondary to iNOS induction plus O2
–· generation
has been implicated as the major factor leading to impaired
mitochondrial respiration in some tissues, such as the rat
diaphragm, following in vivo challenge with LPS [50].
The poly(ADP-ribose) polymerase hypothesis
PARP-1 is a nuclear enzyme that participates in a variety of
cellular functions, including the repair of single-strand breaks
in nuclear DNA [51,52], DNA replication [53], and apoptosis
[53]. PARP-1 is activated by single-strand breaks in nuclear
DNA, and then catalyzes the cleavage of NAD+ into ADP-
ribose and nicotinamide and the polymerization of the resul-
tant ADP-ribose units into branching poly(ADP-ribose)
homopolymers [54,55]. Simultaneously, poly-ADP ribose is
degraded by various nuclear enzymes, especially poly(ADP-
ribose) glycohydrolase [55,56]. The concurrent actions of
PARP-1 and poly(ADP-ribose) glycohydrolase constitute the
functional equivalent of a nicotinamide adenine dinucleoti-
dase. In states of acute inflammation, reactive oxygen species
including ONOO– (and related oxidants) can induced single-
strand breaks in nuclear DNA, and thereby can activate
PARP-1. As a consequence, the NAD+/NADH content of
cells can be depleted. Since NADH is the main reducing
equivalent used to support oxidative phosphorylation, activa-
tion of PARP-1 can lead to a marked impairment in the ability
of cells to utilize O2 to support ATP synthesis; in other words,
cytopathic hypoxia.
The notion that redox stress can lead to PARP-1 activation
and metabolic inhibition on this basis was first articulated by
Schraufstatter et al. about 15 years ago [57]. More recently,
Szabó et al. showed that exposure of cultured cells to physio-
logically relevant concentrations of ONOO– activated
PARP-1 and, on this basis, resulted in impaired mitochondrial
respiration [58]. Szabó and coworkers further showed that
endogenously generated ONOO– was capable of activating
PARP-1 and thereby of inhibiting mitochondrial respiration in
cultured immunostimulated macrophages [59] and vascular
smooth muscle cells [60]. Of note, in these studies, alter-
ations in cellular respiration were not detected by directly
measuring O2 consumption, but were inferred by quantitating
the reduction of MTT [59].
Recent  in vitro studies performed by Khan et al. provide
further support for the importance of PARP-1-dependent
NAD+/NADH depletion as a mechanism for cytopathic
hypoxia caused by inflammatory mediators [61]. Human
Caco-2 enterocytic cells growing on microcarrier beads were
used as a ‘reductionist’ model of the intestinal epithelium. The
consumption of O2 by these cells was measured directly
using an O2-sensitive optode. Incubation of the cells with
cytomix (a cocktail of three proinflammatory cytokines: TNF-α,
IL-1β, and IFN-γ) decreased cellular O2 consumption by more
than 50% (Fig. 5a). This phenomenon was entirely reversible;
if the cells were washed free of the cytokine cocktail and then
incubated for a short period in normal culture medium, the
normal rate of O2 consumption was restored (Fig. 5b). The
cytokine-induced decrease in O2 consumption was thus not
caused by cell death, but by some sublethal process that
impaired normal cellular respiration.
The decrease in O2 consumption induced by incubation with
cytomix was significantly ameliorated if any one of the follow-
ing pharmacological agents was also present during the
period of exposure to the cytokine cocktail: 4,5-dihydroxy-1,3-
benzene disulfonic acid, an O2
–· scavenger; 2-(4-carboxy-
phenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide, a NO·
scavenger; 5,10,15,20-tetrakis-[4-sulfonatophenyl]-porphyri-
nato-iron[III], a ONOO– decomposition catalyst; urate, a
Critical Care    December 2002 Vol 6 No 6 Fink497
ONOO– scavenger; 3-aminobenzamide, a PARP-1 inhibitor;
or  N-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethyl-
acetamide HCl, a chemically dissimilar and more potent
PARP-1 inhibitor [61]. The decrease in O2 uptake induced by
cytomix was associated with significantly decreased cellular
levels of NAD+/NADH.
Khan et al. reasoned that if NAD+/NADH depletion is respon-
sible for the decrease in cellular respiration induced by
cytomix, then replenishing cellular levels of this catalytically
essential nucleotide should tend to restore normal rates of O2
consumption [61]. NAD+, however, is a bulky and highly
charged molecule that would not be expected to diffuse
across the cytosolic membrane. Furthermore, extracellular
NAD+/NADH is a substrate for a cell-surface enzyme, nicoti-
namide adenine dinucleotide glycohydrolase, which converts
NAD+/NADH into cyclic ADP-ribose [62]. Simply adding
NAD+ or NADH to the incubation medium would thus not be
expected to have much of an effect on cellular levels of
NAD+/NADH. In an effort to circumvent this problem, the
investigators incubated cytomix-stimulated Caco-2 cells with
NAD+ encapsulated in liposomes. This strategy worked;
when cytomix-stimulated Caco-2 cells were coincubated with
liposome-encapsulated NAD+, the cellular NAD+/NADH level
was increased to about 85% of the control value (Fig. 6). Fur-
thermore, coincubating cytomix-stimulated Caco-2 cells with
liposome-encapsulated NAD+ prevented the development of
cytopathic hypoxia (Fig. 7).
In addition to the findings just described, other data support
the view that PARP-1 activation is a major factor contributing
to the pathogenesis of sepsis. For example, using pharmaco-
logical agents to block PARP-1 can prevent LPS-induced
vascular contractile dysfunction in rodents [63,64]. Moreover,
in comparison with wild-type controls, mice with a genetic
defect in the PARP-1 enzyme (i.e. PARP-1 knockout mice)
are relatively resistant to the lethal of effects LPS [65,66].
Goldfarb et al. recently showed that treatment with a potent
PARP-1 inhibitor (N-[6-oxo-5,6-dihydro-phenanthridin-2-yl]-
N,N-dimethylacetamide HCl) significantly improved survival in
a porcine model of lethal bacterial peritonitis [67].
Conclusion
Several lines of evidence support the notion that cellular ener-
getics are deranged in established sepsis not on the basis of
Available online http://ccforum.com/content/6/6/491
Figure 5
Effect of incubation with cytomix on O2 consumption by Caco-2
enterocytes. (a) In some studies, O2 consumption was measured after
cells growing on microcarrier beads were incubated for 24 hours with
either control medium (Control24; n = 11) or medium containing
cytomix (Cyto24; n = 12). (b) In additional experiments, enterocytes
that had been exposed to cytomix for 24 hours were washed
extensively, and then incubated for a further 4 hours with either
cytokine-free medium (Cyto24/Control4; n = 9) or cytomix-containing
medium (Cyto24/Cyto4; n = 4). Data were analyzed using Student’s t
test. * P < 0.05 versus Control24, † P < 0.05 versus Cyto24/Control4.
Reprinted from [61] with permission.
Figure 6
Effect of liposomal nicotinamide adenine dinucleotide (NAD+) on
NAD+/NADH levels in Caco-2 enterocytes. Caco-2 cells growing as
monolayers in six-well chambers were incubated for 24 hours under
cytokine-free conditions alone (Control) or with cytomix in the
presence or absence of free NAD+ (NAD), of empty liposomes (Lipo),
or of NAD+-containing liposomes (LipoNAD). Results are means ±
SEM (n = 4 per condition). Data were analyzed by analysis of variance
followed by Duncan’s multiple range test. * P < 0.05 versus control, †
P < 0.05 versus Cyto. Reprinted from [61] with permission.498
inadequate tissue perfusion, but rather on the basis of
impaired mitochondrial respiration. If this concept is correct,
then a promising approach will be to develop pharmacological
strategies, notably potent and selective PARP-1 inhibitors, to
restore normal mitochondrial function and cellular energetics.
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